Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Table 2 Treatment response

Before matching	Anti-PD-1 plus sorafenib (n = 58)		Anti-PD-1 alone (n = 82)		p value
ORR	13	22.4%	16	19.5%	0.68
DCR	40	69.0%	31	37.8%	< 0.05
CR	5	8.6%	4	4.9%
PR	8	13.8%	12	14.6%
SD	27	46.6%	15	18.3%
After matching	Anti-PD-1 plus sorafenib (n = 58)		Anti-PD-1 alone (n = 42)		p value
ORR	13	22.4%	9	21.4%	0.91
DCR	40	69.0%	14	33.3%	< 0.05
CR	5	8.6%	3	7.1%
PR	8	13.8%	6	14.3%
SD	27	46.6%	5	11.9%

CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease-control rate

ISSN: 1471-2407